Risk factors for hepatocellular carcinoma in hepatitis C patients with sustained virologic response to interferon therapy

Liver International

Volumn 24, Issue 6, 2004, Pages 603-610

  Iwasaki, Yoshiaki ^a   Takaguchi, Kouichi ^b   Ikeda, Hiroshi ^c   Makino, Yasuhiro ^d   Araki, Yasuyuki ^e   Ando, Masaharu ^f   Kobashi, Haruhiko ^g   Kobatake, Toshitsugu ^h   Tanaka, Ryoji ⁱ   Tomita, Minoru ^j   Senoh, Tomonori ^k   Kawaguchi, Mitsuhiko ^l   Shimoe, Toshinari ^m   Manabe, Koji ⁿ   Kita, Keiji ^b   Shimamura, Junnosuke ^c   Sakaguchi, Kohsaku ^a   Shiratori, Yasushi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b KAGAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^c KURASHIKI CENTRAL HOSPITAL   (Japan)

^d IWAKUNI NATIONAL HOSPITAL   (Japan)

^e HIROSHIMA CITY HOSPITAL   (Japan)

^f Mitoyo General Hospital   (Japan)

^g Tsuyama Central Hospital   (Japan)

^h Teraoka Memorial Hospital   (Japan)

ⁱ Department of Surgery   (Japan)

^j Mihara Red Cross Hospital   (Japan)

^k Fukuyama National Hospital   (Japan)

^l OKAYAMA SAISEIKAI GENERAL HOSPITAL   (Japan)

^m Fukuyama City Hospital   (Japan)

ⁿ Shigei Medical Research Institute and Hospital   (Japan)

more..

Author keywords

Hepatic fibrosis; Hepatitis C; Hepatocellular carcinoma; Interferon; Risk factor; Sustained virologic response

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; INTERFERON; RECOMBINANT ALPHA INTERFERON;

ADULT; AGE; AGED; ALCOHOL CONSUMPTION; ARTICLE; CANCER GRADING; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; CLINICAL OBSERVATION; CONTROLLED STUDY; DRUG RESPONSE; ERADICATION THERAPY; FEMALE; FOLLOW UP; FREQUENCY ANALYSIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER FIBROSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NONBIOLOGICAL MODEL; NONHUMAN; PERIODIC MEDICAL EXAMINATION; REGRESSION ANALYSIS; RISK FACTOR; SCORING SYSTEM; STATISTICAL SIGNIFICANCE;

ADULT; AGE DISTRIBUTION; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; COMORBIDITY; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; INTERFERON ALFA-2A; LIVER NEOPLASMS; MALE; MIDDLE AGED; PRECANCEROUS CONDITIONS; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SEX DISTRIBUTION; STATISTICS, NONPARAMETRIC; VIRAL LOAD;

EID: 19944374418     PISSN: 14783223     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2004.0956.x     Document Type: Article

References (37)

1. Wong F, Choi T K. Primary liver cancer. Asian experience. In: Blumgart L H, ed. Surgery of Liver and Biliary Tract. London: Churchill-Livingstone, 1988; 1135-51.
2. Shiratori Y, Shiina S, Imamura M, et al. Characteristic difference of hepatocellular carcinoma between hepatitis B- and C- viral infection in Japan. Hepatology 1995; 22: 1027-33.
3. Tanaka K, Hirohata T, Koga S, et al. Hepatitis C and hepatitis B in the etiology of hepatocellular carcinoma in the Japanese population. Cancer Res 1991; 51: 2842-7.
4. Yokosuka O, Kojima H, Imazeki F, et al. Spontaneous negativation of serum hepatitis C virus RNA is a rare event in type C chronic liver diseases: analysis of HCV RNA in 320 patients who were followed for more than 3 years. J Hepatol 1999; 31: 394-9.
5. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-32.
6. Yano M, Kumada H, Kage M. et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996; 23: 1334-40.
7. Di Bisceglie A M. Hepatitis C and hepatocellular carcinoma. Semin Liver Dis 1995; 15: 64-9.
8. Kato Y, Nakata K, Omagari K, et al. Risk of hepatocellular carcinoma in patients with cirrhosis in Japan. Analysis of infectious hepatitis viruses. Cancer 1994; 74: 2234-8.
9. Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology 1995; 21: 650-5.
10. Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 1999; 131: 174-81.
11. McHutchison J G, Gordon S C, Schiff E R, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-92.
12. Poynard T, Marcellin P, Lee S S, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 1426-32.
13. Manns M P, McHutchison J G, Gordon S C, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
14. Fried M W, Shiffman M L, Reddy K R, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
15. Kasahara A, Hayashi N, Mochizuki K, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology 1998; 27: 1394-1402.
16. Imai Y, Kawata S, Tamura S, et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med 1998; 129: 94-9.
17. Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-5.
18. Serfaty L, Aumaitre H, Chazouilleres O, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998; 27: 1435-40.
19. Lau J Y, Davis G L, Kniffen J, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993; 341: 1501-4.
20. Okamoto H, Sugiyama Y, Okada S, et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol 1992; 673-9.
21. Tanaka T, Tsukiyama K K, Yamaguchi K, et al. Significance of specific antibody assay for genotyping of hepatitis C virus. Hepatology 1994; 19: 1347-53.
22. Shiratori Y, Kato N, Yokosuka O, et al. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group. Gastroenterology 1997; 113: 558-66.
23. Desmet V J, Gerber M, Hoofnagle J H, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513-20.
24. Reichard O, Glaumann H, Fryden A, et al. Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment. Hepatology 1995; 21: 918-22.
25. Collins W P, Loeffler R K, Tivery H. Observation of growth rates of human tumors. Am J Roentgenol 1956; 76: 988-1294.
26. Schwartz M. A biochemical approach to clinical tumor growth. Cancer 1961; 14: 1272-94.
27. Toyoda H, Kumada T, Tokuda A, et al. Long-term follow-up of sustained responders to interferon therapy, in patients with chronic hepatitis C. J Viral Hepatol 2000; 7: 414-9.
28. Koike Y, Shiratori Y, Sato S, et al. Risk factors for recurring hepatocellular carcinoma differ according to infected hepatitis virus - an analysis of 236 consecutive patients with a single lesion. Hepatology 2000; 32: 1216-23.
29. Shiratori Y, Imazeki F, Moriyama M, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000; 132: 517-24.
30. Toyoda H, Kumada T, Honda T, et al. Analysis of hepatocellular carcinoma tumor growth detected in sustained responders to interferon in patients with chronic hepatitis C. J Gastroenterol Hepatol 2001; 16: 1131-7.
31. Ebara M, Ohto M, Shinagawa T, et al. Natural history of minute hepatocellular carcinoma smaller than three centimeters complicating cirrhosis. A study in 22 patients. Gastroenterology 1986; 90: 289-98.
32. Yamagata M, Masaki T, Okudaira T, et al. Small hyperechoic nodules in chronic liver diseases include hepatocellular carcinomas with low cyclin D1 and Ki-67 expression. Hepatology 1999; 29: 1722-9.
33. Feitelson M A, Sun B, Satiroglu T N, Liu J, Pan J, Lian Z. Genetic mechanisms of hepatocarcinogenesis. Oncogene 2002; 21: 2593-604.
34. Tsutsumi M, Ishizaki M, Takada A. Relative risk for the development of hepatocellular carcinoma in alcoholic patients with cirrhosis: a multiple logistic-regression coefficient analysis. Alcohol Clin Exp Res 1996; 20: 758-62.
35. Tsutsumi M, Matsuda Y, Takada A. Role of ethanol-inducible cytochrome P-450 2E1 in the development of hepatocellular carcinoma by the chemical carcinogen, N-nitrosodimethylamine. Hepatology 1993; 18: 1483-9.
36. Yokoyama H, Ishii H, Nagata S, Kato S, Kamegaya K, Tsuchiya M. Experimental hepatitis induced by ethanol after immunization with acetaldehyde adducts. Hepatology 1993; 17: 14-9.
37. Matsuhashi T, Yamada N, Shinzawa H, Takahashi T. Effect of alcohol on tumor growth of hepatocellular carcinoma with type C cirrhosis. Intern Med 1996; 35: 443-8.